Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 20;5(24):5565–5573. doi: 10.1182/bloodadvances.2021005538

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PMC Copyright notice

Figure 2. — Predictive value of baseline variables for favoring IC or ven/aza. (A) Factors that favored the likelihood of achieving a response (CR or CRi) to IC vs ven/aza. RUNX1 mutation plus age ≥65 years was assessed but not estimable. (B) Factors that favored OS for IC compared with ven/aza. (C) In a cohort of patients propensity matched for age, ELN risk group, and transplantation status, factors that favored OS for IC vs ven/aza. Variables that were assessed but not estimable included NPM1 mutation plus age ≥65 years and RUNX1 mutation plus age ≥65 years.

Figure 2. — Predictive value of baseline variables for favoring IC or ven/aza. (A) Factors that favored the likelihood of achieving a response (CR or CRi) to IC vs ven/aza. RUNX1 mutation plus age ≥65 years was assessed but not estimable. (B) Factors that favored OS for IC compared with ven/aza. (C) In a cohort of patients propensity matched for age, ELN risk group, and transplantation status, factors that favored OS for IC vs ven/aza. Variables that were assessed but not estimable included NPM1 mutation plus age ≥65 years and RUNX1 mutation plus age ≥65 years.